Aarey Drugs & Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDOil Gas & Consumable Fuels
Sector economics are clouded by input volatility and uneven volume trends. WPI fuel inflation is very high at 20.05% (Jul/26), crude oil output is -5.3% YoY (2026-07), natural gas is -3.7% YoY (2026-07), and natural gas consumption is -3.0% YoY (2026-06), although refinery products grew 2.7% YoY (2026-07) and coal was 7.6% YoY (2026-07). Heavy FPI outflows of INR -15293 crore over 3 months to 2026-08-31 and negative oil-linked news flow reinforce the underweight.
PROS
- Institutional investors have been accumulating - FII+DII up 2.8pp
- Company maintains a comfortable, low leverage position
- Company converts assets efficiently - asset turnover of 1.6x
CONS
- A large part of profit comes from other income (160.8% of PBT)
- Company has a low return on equity of 3.4% over last 3 years
- Company has a low return on capital employed of 6.2%
- Promoter holding has decreased over last 2 years: -7.6pp
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.48x)
- Operating cash flow has been negative in recent years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ADANIENT | 3057.10 | 55.59 | 413846.54 | 0.04 | -1461.54 | -249.67 | 32923.98 | 49.92 | 13.30 | 15.57 |
| AEGISLOG | 1353.10 | 37.96 | 47493.81 | 0.64 | 544.84 | 210.70 | 2356.86 | 37.07 | 19.76 | 30.28 |
| CPPLUS | 3830.15 | 94.94 | 45310.84 | 0.04 | 142.20 | 332.51 | 1402.42 | 89.51 | 29.48 | 14.52 |
| PREMIERENE | 974.55 | 26.57 | 44239.84 | 0.10 | 471.92 | 53.32 | 2462.59 | 35.25 | 33.72 | 29.03 |
| REDINGTON | 393.65 | 18.09 | 30774.55 | 1.52 | 453.49 | 94.65 | 34922.47 | 34.57 | 18.96 | 2.03 |
| HONASA | 470.95 | 61.70 | 15354.11 | 0.64 | 90.45 | 118.87 | 755.95 | 27.00 | 20.87 | 14.58 |
| LLOYDSENT | 69.79 | 94.88 | 10653.81 | 0.21 | 109.98 | -55.77 | 563.03 | 70.15 | 12.84 | 18.07 |
| SGMART | 751.25 | 76.16 | 9468.39 | 0.00 | 455.80 | 1310.71 | 13085.70 | 1044.08 | 10.43 | 4.49 |
| MMTC | 61.96 | 20.78 | 9294.00 | 0.00 | 104.24 | 135.52 | 0.68 | -50.00 | 33.46 | -1423.53 |
| ENTERO | 1819.35 | 63.14 | 7918.37 | 0.00 | 52.05 | 72.17 | 1940.50 | 38.23 | 10.93 | 5.00 |
| EBGNG | 683.00 | 54.67 | 7786.99 | 0.00 | 28.93 | 56.21 | 412.46 | 32.08 | 20.58 | 11.97 |
| AAREYDRUGS | 99.23 | 73.36 | 306.37 | 0.00 | 1.02 | -25.26 | 44.63 | -56.34 | 6.38 | 2.97 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51 | 58 | 76 | 210 | 127 | 105 | 134 | 108 | 102 | 84 | 96 | 189 | 45 | |
| 50 | 56 | 74 | 212 | 126 | 101 | 132 | 112 | 101 | 82 | 98 | 185 | 46 | |
| Operating Profit | 1 | 2 | 3 | -1 | 1 | 4 | 2 | -4 | 2 | 3 | -2 | 4 | -1 |
| OPM % | 2.63% | 3.20% | 3.54% | -0.68% | 0.93% | 3.54% | 1.64% | -3.89% | 1.66% | 3.14% | -1.57% | 2.29% | -2.69% |
| 1 | 1 | 0 | 5 | 2 | 0 | 1 | 8 | 2 | 1 | 4 | -0 | 2 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before Tax | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Tax % | 0.00% | 21.78% | 30.14% | -0.47% | 6.77% | 8.57% | 48.57% | 71.60% | 20.81% | 31.08% | 38.04% | -21.88% | -98.64% |
| Net Profit | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 1 |
| 0.29 | 0.31 | 0.40 | 0.77 | 0.44 | 0.57 | 0.26 | 0.17 | 0.48 | 0.36 | 0.20 | 0.55 | 0.36 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 246 | 396 | 349 | 355 | 300 | 348 | 493 | 419 | 398 | 474 | 415 | |
| 245 | 386 | 341 | 347 | 297 | 344 | 481 | 411 | 391 | 471 | 410 | |
| Operating Profit | 1 | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 6 | 3 | 4 |
| OPM % | 0.41% | 2.43% | 2.19% | 2.22% | 1.08% | 1.33% | 2.31% | 1.84% | 1.63% | 0.61% | 1.03% |
| 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | 5 | 10 | 6 | |
| Interest | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit before Tax | 2 | 8 | 8 | 9 | 7 | 8 | 10 | 6 | 5 | 6 | 4 |
| Tax % | 28.88% | 31.39% | 24.59% | 27.20% | 20.00% | 21.53% | 34.69% | 37.25% | 12.34% | 34.05% | 0.52% |
| Net Profit | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 4 | 4 |
| EPS | 0.77 | 3.03 | 2.64 | 2.64 | 2.80 | 2.79 | 2.72 | 1.49 | 1.67 | 1.41 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 3.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 8%
- 5 Years:
- 10%
- 3 Years:
- -1%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 14%
- 5 Years:
- -7%
- 3 Years:
- -15%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- 22%
- 3 Years:
- 26%
- 1 Year:
- 34%
RETURN ON EQUITY
- 10 Years:
- 6%
- 5 Years:
- 5%
- 3 Years:
- 3%
- Last Year:
- 3%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 18 | 23 | 23 | 23 | 23 | 25 | 25 | 28 | 28 |
| 20 | 30 | 55 | 61 | 67 | 73 | 86 | 90 | 102 | 108 | |
| 15 | 10 | 3 | 16 | 18 | 18 | 14 | 38 | 31 | 35 | |
| Trade Payables | 72 | 75 | 78 | 37 | 78 | 110 | 110 | 127 | 129 | 103 |
| 2 | 9 | 11 | 8 | 8 | 8 | 10 | 11 | 13 | 17 | |
| Total Liabilities | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 |
| 8 | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 13 | 16 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | |
| 2 | 5 | 15 | 21 | 17 | 18 | 14 | 29 | 35 | 45 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 184 | 133 | |
| Cash & Bank | 2 | 1 | 3 | 0 | 1 | 1 | 0 | 1 | 2 | 1 |
| 113 | 124 | 139 | 111 | 164 | 199 | 216 | 247 | 68 | 92 | |
| Total Assets | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 3 | -18 | 3 | 4 | 7 | 4 | 1 | -3 | 10 | |
| Cash from Investing | -3 | -5 | -1 | -1 | -1 | -3 | -3 | 0 | -2 | -6 |
| Cash from Financing | -2 | 4 | 23 | -2 | -2 | -2 | 2 | 1 | 6 | -4 |
| 1 | -1 | 2 | -3 | 0 | 0 | -0 | 1 | 1 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-11 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about the AGM Intimation letter that has been sent to the Shareholders under Regulation 36(1)(b) of the SEBI Listing Regulations, 2015
2026-09-09 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
2026-09-08 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
2026-09-08 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding ''.Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding 'Intimation of Book Closure/ E-Voting period for the 36th Annual General Meeting
2026-09-05 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 05, 2026.
2026-08-20 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-14 - Aarey Drugs & Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the period ended Jun 30, 2026.
2026-08-06 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 06, 2026.
2026-07-08 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
News
Recent coverage and analyst commentary for AAREYDRUGS
Loading news…
AI Stock Analyst
Aarey Drugs & Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account